CABA (Cabaletta Bio) ROE % Adjusted to Book Value: -55.74% (As of Mar. 2026)


CABA Cabaletta Bio Inc CABA
34 GF Score
Price $3.02
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio ROE % Adjusted to Book Value?

Cabaletta Bio CABA -0.49% 34 ROE % Adjusted to Book Value is -55.74% as of Mar. 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Cabaletta Bio's ROE % for the quarter that ended in Mar. 2026 was -161.65%. Cabaletta Bio's PB Ratio for the quarter that ended in Mar. 2026 was 2.90. Cabaletta Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -55.74%.

Cabaletta Bio ROE % Adjusted to Book Value Related Terms

Cabaletta Bio ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio ROE % Adjusted to Book Value Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -43.75 -18.25 -8.91 -78.47 -64.79

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -181.02 -154.27 -70.12 -68.03 -55.74

CABA vs DNA, CADL, CLYM: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Cabaletta Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cabaletta Bio ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cabaletta Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cabaletta Bio's ROE % Adjusted to Book Value falls into.


CABA
34GF Score
Cabaletta Bio Inc CABA
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cabaletta Bio ROE % Adjusted to Book Value Calculation

Cabaletta Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-126.98% / 1.96
=-64.79%

Cabaletta Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-161.65% / 2.90
=-55.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -55.74% mean?
Cabaletta Bio (CABA) has a ROE % Adjusted to Book Value of -55.74% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cabaletta Bio and its competitors.
Is Cabaletta Bio's ROE % Adjusted to Book Value too high?
Cabaletta Bio's current ROE % Adjusted to Book Value is -55.74%. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's ROE % Adjusted to Book Value compare to DNA and CADL?
Cabaletta Bio's ROE % Adjusted to Book Value of -55.74% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cabaletta Bio and its competitors. Cabaletta Bio's current ROE % Adjusted to Book Value is -55.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current ROE % Adjusted to Book Value of -55.74%. The current ROE % Adjusted to Book Value is -55.74%. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current ROE % Adjusted to Book Value is -55.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:Mexico
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score

Get the complete analysis for CABA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.02
Price